Alkermes plc with ticker code (ALKS) now have 12 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The target price ranges between 28 and 16 calculating the average target price we see 21.17. Now with the previous closing price of 14.02 this would imply there is a potential upside of 51.0%. There is a 50 day moving average of 16.77 and the 200 day MA is 18.86. The market cap for the company is $2,228m. Company Website: http://www.alkermes.com
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.